The DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.
Targeting Apoptosis Pathways in Cancer Therapy
Open accessAbstract
Apoptosis, or programmed cell death, is a mechanism by which cells undergo death to control cell proliferation or in response to DNA damage. The understanding of apoptosis has provided the basis for novel targeted therapies that can induce death in cancer cells or sensitize them to established cytotoxic agents and radiation therapy. These novel agents include those targeting the extrinsic pathway such as tumor necrosis factor-related apoptosis-inducing ligand receptor 1, and those targeting the intrinsic Bcl-2 family pathway such as antisense bcl-2 oligonucleotides. Many pathways and proteins control the apoptosis machinery. Examples include p53, the nuclear factor kappa B, the phosphatidylinositol 3 kinase pathway, and the ubiquitin/proteosome pathway. These can be targeted by specific modulators such as bortezomib, and mammalian target of rapamycin inhibitors such as CCI-779 and RAD 001. Because these pathways may be preferentially altered in tumor cells, there is potential for a selective effect in tumors sparing normal tissue. This article reviews the current understanding of the apoptotic pathways, including the extrinsic (cytoplasmic) and intrinsic (mitochondrial) pathways, and the agents being developed to target these pathways.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Thornberry, N. A., & Lazebnik, Y. (1998) · Science · doi:10.1126/science.281.5381.1312 · Cited by 6,887
Hengartner, M. O. (2000) · Nature · doi:10.1038/35037710 · Cited by 5,779
The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621
Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death
Hockenbery, D., Nuñez, G., Milliman, C., Schreiber, R. D., & Korsmeyer, S. J. (1990) · Nature · doi:10.1038/348334a0 · Cited by 3,720
Two CD95 (APO‐1/Fas) signaling pathways
Scaffidi, C., Fulda, S., Srinivasan, A., Friesen, C., Li, F., Tomaselli, K. J., Debatin, K., Krammer, P. H., & Peter, M. E. (1998) · The EMBO Journal · doi:10.1093/emboj/17.6.1675 · Cited by 3,000
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Bcl-2 and the regulation of programmed cell death
Reed, J. (1994) · The Journal of cell biology · doi:10.1083/jcb.124.1.1 · Cited by 2,305
Cantley, L. C., & Neel, B. G. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4240 · Cited by 2,006
Lethal effect of the anti-Fas antibody in mice
Ogasawara, J., Watanabe-Fukunaga, R., Adachi, M., Matsuzawa, A., Kasugai, T., Kitamura, Y., Itoh, N., Suda, T., & Nagata, S. (1993) · Nature · doi:10.1038/364806a0 · Cited by 1,881
Lowe, S. W., & Lin, A. W. (2000) · Carcinogenesis · doi:10.1093/carcin/21.3.485 · Cited by 1,876
Involvement of the bcl -2 Gene in Human Follicular Lymphoma
Tsujimoto, Y., Cossman, J., Jaffe, E., & Croce, C. M. (1985) · Science · doi:10.1126/science.3874430 · Cited by 1,786
Tsujimoto, Y., Finger, L. R., Yunis, J., Nowell, P. C., & Croce, C. M. (1984) · Science · doi:10.1126/science.6093263 · Cited by 1,769
The Receptor for the Cytotoxic Ligand TRAIL
Pan, G., O'Rourke, K., Chinnaiyan, A. M., Gentz, R., Ebner, R., Ni, J., & Dixit, V. M. (1997) · Science · doi:10.1126/science.276.5309.111 · Cited by 1,767
CD95's deadly mission in the immune system
Krammer, P. H. (2000) · Nature · doi:10.1038/35037728 · Cited by 1,717
Proteasome inhibitors: a novel class of potent and effective antitumor agents.
Adams, J., Palombella, V. J., Sausville, E. A., Johnson, J. I., Destree, A. T., Lazarus, D. D., Maas, J., Pien, C. S., Prakash, S., & Elliott, P. J. (1999) · PubMed · Cited by 1,477
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR
Neshat, M. S., Mellinghoff, I. K., Tran, C., Stiles, B., Thomas, G., Petersen, R., Frost, P., Gibbons, J. J., Wu, H., & Sawyers, C. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171076798 · Cited by 969
The Fas Signaling Pathway: More Than a Paradigm
Wajant, H. (2002) · Science · doi:10.1126/science.1071553 · Cited by 957
Atkins, M. B., Hidalgo, M., Stadler, W. M., Logan, T. F., Dutcher, J. P., Hudes, G. R., Park, Y., Liou, S.-H., Marshall, B., Boni, J. P., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.185 · Cited by 942
NF-κB as a Therapeutic Target in Multiple Myeloma
Hideshima, T., Chauhan, D., Richardson, P., Mitsiades, C., Mitsiades, N., Hayashi, T., Munshi, N., Dang, L., Castro, A., Palombella, V., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200360200 · Cited by 893
Jo, M., Kim, T.-H., Seol, D.-W., Esplen, J. E., Dorko, K., Billiar, T. R., & Strom, S. C. (2000) · Nature Medicine · doi:10.1038/75045 · Cited by 843
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma
Jagannath, S., Barlogie, B., Berenson, J., Siegel, D., Irwin, D., Richardson, P. G., Niesvizky, R., Alexanian, R., Limentani, S. A., Alsina, M., et al. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05188.x · Cited by 740
Mechanisms of cytochrome c release by proapoptotic BCL-2 family members
Scorrano, L., & Korsmeyer, S. J. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)00615-6 · Cited by 716
Programmed cell death: alive and well in the new millennium
Kaufmann, S. H., & Hengartner, M. O. (2001) · Trends in Cell Biology · doi:10.1016/s0962-8924(01)02173-0 · Cited by 673
Korsmeyer, S. J. (1995) · Trends in Genetics · doi:10.1016/s0168-9525(00)89010-1 · Cited by 648
Rinehart, J., Adjei, A. A., LoRusso, P. M., Waterhouse, D., Hecht, J. R., Natale, R. B., Hamid, O., Varterasian, M., Asbury, P., Kaldjian, E. P., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.185 · Cited by 645
Self-citationThe rapamycin-sensitive signal transduction pathway as a target for cancer therapy
Hidalgo, M., & Rowinsky, E. K. (2000) · Oncogene · doi:10.1038/sj.onc.1204091 · Cited by 582
Proteasome Inhibition As a Novel Therapeutic Target in Human Cancer
Rajkumar, S. V., Richardson, P. G., Hideshima, T., & Anderson, K. C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.030 · Cited by 569
PUMA mediates the apoptotic response to p53 in colorectal cancer cells
Yu, J., Wang, Z., Kinzler, K. W., Vogelstein, B., & Zhang, L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2627984100 · Cited by 563
FLICE-Inhibitory Proteins: Regulators of Death Receptor-Mediated Apoptosis
Krueger, A., Baumann, S., Krammer, P. H., & Kirchhoff, S. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.24.8247-8254.2001 · Cited by 549
The proteasome: a novel target for cancer chemotherapy
Almond, J., & Cohen, G. (2002) · Leukemia · doi:10.1038/sj.leu.2402417 · Cited by 538
Wen, Y., Hu, M. C. ‐., Makino, K., Spohn, B., Bartholomeusz, G. A., Yan, D., & Hung, M. (2000) · PubMed · Cited by 531
The proteasome inhibitor PS-341 in cancer therapy.
Teicher, B. A., Ara, G., Herbst, R. S., Palombella, V. J., & Adams, J. (1999) · PubMed · Cited by 521
Miyashita, T., & Reed, J. C. (1992) · PubMed · Cited by 475
Epidermal Growth Factor Receptor-dependent Akt Activation by Oxidative Stress Enhances Cell Survival
Wang, X., McCullough, K. D., Franke, T. F., & Holbrook, N. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.19.14624 · Cited by 460
Waters, J. S., Webb, A., Cunningham, D., Clarke, P. A., Raynaud, F., di Stefano, F., & Cotter, F. E. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.9.1812 · Cited by 454
The ubiquitin‐proteasome pathway and proteasome inhibitors
Myung, J., Kim, K. B., & Crews, C. M. (2001) · Medicinal Research Reviews · doi:10.1002/med.1009 · Cited by 446
Mancini, M., Nicholson, D. W., Roy, S., Thornberry, N. A., Peterson, E. P., Casciola-Rosen, L. A., & Rosen, A. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.140.6.1485 · Cited by 408
Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies.
Kakkar, V. V. (1997) · PubMed · Cited by 398
Altucci, L., Rossin, A., Raffelsberger, W., Reitmair, A., Chomienne, C., & Gronemeyer, H. (2001) · Nature Medicine · doi:10.1038/89050 · Cited by 340
Apoptosis-regulating proteins as targets for drug discovery
Reed, J. C. (2001) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(01)02026-3 · Cited by 328
How acute promyelocytic leukaemia revived arsenic
Zhu, J., Chen, Z., Lallemand-Breitenbach, V., & de Thé, H. (2002) · Nature Reviews Cancer · doi:10.1038/nrc887 · Cited by 321
Apoptosis: target of cancer therapy.
Ferreira, C. G., Epping, M. T., Kruyt, F. A. E., & Giaccone, G. (2002) · PubMed · Cited by 283
Havell, E. A., Fiers, W., & North, R. J. (1988) · The Journal of experimental medicine · doi:10.1084/jem.167.3.1067 · Cited by 276
Geoerger, B., Kerr, K., Tang, C. B., Fung, K., Powell, B., Sutton, L. N., Phillips∥, P. C., & Janss, A. J. (2001) · PubMed · Cited by 261
Intravascular adenoviral agents in cancer patients: Lessons from clinical trials
Reid, T., Warren, R., & Kirn, D. (2002) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700539 · Cited by 258
Proteasome Inhibition: a New Strategy in Cancer Treatment
Adams, J., Palombella, V. J., & Elliott, P. J. (2000) · Investigational New Drugs · doi:10.1023/a:1006321828515 · Cited by 248
Mutations in the Fas Antigen in Patients With Multiple Myeloma
Landowski, T. H., Qu, N., Buyuksal, I., Painter, J. S., & Dalton, W. S. (1997) · Blood · doi:10.1182/blood.v90.11.4266 · Cited by 244
Lin, J., Adam, R. M., Santiestevan, E., & Freeman, M. R. (1999) · PubMed · Cited by 241
Antisense therapy in oncology: new hope for an old idea?
Tamm, I., Dörken, B., & Hartmann, G. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05629-x · Cited by 229
A diverse family of proteins containing tumor necrosis factor receptor-associated factor domains.
Zapata, J. M., Pawlowski, K., Haas, E., Ware, C. F., Godzik, A., & Reed, J. C. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100354200 · Cited by 228
Sensibar, J. A., Sutkowski, D. M., Raffo, A. J., Buttyan, R., Griswold, M. D., Sylvester, S. R., Kozlowski, J. M., & Lee, C. (1995) · PubMed · Cited by 219
Apoptosis and cancer drug targeting
Sellers, W. R., & Fisher, D. E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci9053 · Cited by 216
Ravagnan, L., Marzo, I., Costantini, P., Susin, S. A., Zamzami, N., Petit, P. X., Hirsch, F., Goulbern, M., Poupon, M.-F., Miccoli, L., et al. (1999) · Oncogene · doi:10.1038/sj.onc.1202625 · Cited by 210
Zaffaroni, N., & Daidone, M. G. (2002) · Drug Resistance Updates · doi:10.1016/s1368-7646(02)00049-3 · Cited by 206
Isotype-Dependent Inhibition of Tumor Growth In Vivo by Monoclonal Antibodies to Death Receptor 4
Chuntharapai, A., Dodge, K., Grimmer, K., Schroeder, K., Marsters, S. A., Koeppen, H., Ashkenazi, A., & Kim, K. J. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.8.4891 · Cited by 202
New antitumor substances of natural origin
Douros, J., & Suffness, M. (1981) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(81)80006-0 · Cited by 202
p53-dependent pathways of apoptosis
Benchimol, S. (2001) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4400918 · Cited by 201
Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic.
Huang, S., & Houghton, P. J. (2002) · PubMed · Cited by 186
Proteasome inhibition: a novel approach to cancer therapy
Adams, J. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02315-8 · Cited by 180
Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study
De Lena, M., Lorusso, V., Latorre, A., Fanizza, G., Gargano, G., Caporusso, L., Guida, M., Catino, A., Crucitta, E., Sambiasi, D., et al. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00400-7 · Cited by 168
Apoptosis: implications of basic research for clinical oncology
Tamm, I., Schriever, F., & Dörken, B. (2001) · The Lancet Oncology · doi:10.1016/s1470-2045(00)00193-5 · Cited by 166
NFκB Mediates Apoptosis through Transcriptional Activation of Fas (CD95) in Adenoviral Hepatitis
Kühnel, F., Zender, L., Paul, Y., Tietze, M. K., Trautwein, C., Manns, M., & Kubicka, S. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.9.6421 · Cited by 163
Dysregulation of CD95/CD95 Ligand-Apoptotic Pathway in CD3+ Large Granular Lymphocyte Leukemia
Lamy, T., Liu, J. H., Landowski, T. H., Dalton, W. S., & Loughran, T. P. (1998) · Blood · doi:10.1182/blood.v92.12.4771 · Cited by 153
Selzer, E., Schlagbauer‐Wadl, H., Okamoto, I., Pehamberger, H., P�tter, R., & Jansen, B. (1998) · Melanoma Research · doi:10.1097/00008390-199806000-00001 · Cited by 134
Hermine, O., Dombret, H., Poupon, J., Arnulf, B., Lefrère, F., Rousselot, P. H., Damaj, G. L., Delarue, R., Fermand, J. P., Brouet, J. C., et al. (2004) · The Hematology Journal · doi:10.1038/sj.thj.6200374 · Cited by 128
Campiglio, M., Locatelli, A., Olgiati, C., Normanno, N., Somenzi, G., Viganò, L., Fumagalli, M., Ménard, S., & Gianni, L. (2003) · Journal of Cellular Physiology · doi:10.1002/jcp.10411 · Cited by 125
Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma
Hussein, M. A., Saleh, M. N., Ravandi, F., Mason, J. R., Rifkin, R. M., & Ellison, R. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.04941.x · Cited by 118
Phase II Study of Lonidamine and Diazepam in the Treatment of Recurrent Glioblastoma Multiforme
Oudard, S. M., Carpentier, A., Banu, E., Fauchon, F., Célérier, D., Poupon, M. F., Dutrillaux, B., Andrieu, J. M., & Delattre, J. ‐. (2003) · Journal of Neuro-Oncology · doi:10.1023/a:1023756707900 · Cited by 117
Role of histone deacetylase inhibitors in the treatment of cancer (Review)
Mei, S., Ho, A. D., & Mahlknecht, U. (2004) · International Journal of Oncology · doi:10.3892/ijo.25.6.1509 · Cited by 109
Ackermann, E. J., Taylor, J. K., Narayana, R., & Bennett, C. F. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.16.11245 · Cited by 104
Villalona-Calero, M. A., Ritch, P. S., Figueroa, J. A., Otterson, G. A., Belt, R. J., Dow, E., George, S., Leonardo, J. M., McCachren, S., Miller, G. L., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0779 · Cited by 88
El-Zawahry, A. M., McKillop, J. C., & Voelkel‐Johnson, C. (2005) · BMC Cancer · doi:10.1186/1471-2407-5-2 · Cited by 85
Wu, J., Ling, X., Pan, D., Apontes, P., Song, L., Liang, P., Altieri, D. C., Beerman, T. A., & Li, F. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m409350200 · Cited by 83
Chen, T., Turner, J. G., McCarthy, S. M., Scaltriti, M., Bettuzzi, S., & Yeatman, T. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2077 · Cited by 82
Clinical development of mammalian target of rapamycin inhibitors
Dancey, J. E. (2002) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(02)00051-5 · Cited by 81
Papaldo, P., Lopez, M., Cortesi, E., Cammilluzzi, E., Antimi, M., Terzoli, E., Lepidini, G., Vici, P., Barone, C. A., Ferretti, G., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.034 · Cited by 78
Acute promyelocytic leukemia: Cellular and molecular basis of differentiation and apoptosis
Chen, Z., Wang, Z.-Y., & Chen, S. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(97)00090-9 · Cited by 74
Lickliter, J. D., Wood, N. J., Johnson, L., McHugh, G., Tan, J., Wood, F. D., Cox, J. M., & Wickham, N. W. R. (2003) · Leukemia · doi:10.1038/sj.leu.2403102 · Cited by 70
Wolf, J. K., Bodurka, D. C., Gano, J. B., Deavers, M. T., Ramondetta, L. M., Ramirez, P. T., Levenback, C., & Gershenson, D. M. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.05.041 · Cited by 69
Raf and the road to cell survival: a tale of bad spells, ring bearers and detours
Troppmair, J., & Rapp, U. R. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(03)00483-0 · Cited by 66
Modulation of NF-κB, p53 and Bcl-2 in apoptosis induced by cisplatin in HeLa cells
Maldonado, V., Meléndez-Zajgla, J., & Ortega, A. (1997) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s0027-5107(97)00150-4 · Cited by 64
The viral death effector Apoptin reveals tumor-specific processes
Rohn, J. L., & Noteborn, M. H. M. (2004) · APOPTOSIS · doi:10.1023/b:appt.0000025808.48885.9c · Cited by 56
Elit, L. M. (2002) · PubMed · Cited by 43
Clusterin and IGFBPs as Antisense Targets in Prostate Cancer
Gleave, M. E., & Jansen, B. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1281.020 · Cited by 39
Rai, K. R., Moore, J. O., Boyd, T. E., Larratt, L. M., Голенков, А. К., Koziner, B., Chanan-Khan, A. A., Bociek, R. G., & Itri, L. M. (2004) · Blood · doi:10.1182/blood.v104.11.338.338 · Cited by 37
CD95 Antigen Mutations in Hematopoietic Malignancies
Landowski, T. H., Moscinski, L. C., Burke, R., Buyuksal, I., Painter, J. S., Goldstein, S., & Dalton, W. S. (2001) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190109097702 · Cited by 29
Heat shock protein and proteasome targeting agents
Takimoto, C. H. M., & Diggikar, S. (2002) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(02)00048-5 · Cited by 20
Effects of the farnesyl transferase inhibitor R115777 on normal and leukemic hematopoiesis
Liesveld, J. L., Lancet, J. E., Rosell, K. E., Menon, A., Lu, C., McNair, C., Abboud, C. N., & Rosenblatt, J. D. (2003) · Leukemia · doi:10.1038/sj.leu.2403063 · Cited by 19
Apoptosis Induced by Molecular Targeting Therapy in Hematological Malignancies
Adachi, S., Leoni, L. M., Carson, D. A., & Nakahata, T. (2003) · Acta Haematologica · doi:10.1159/000074490 · Cited by 19
Regulators of apoptosis as anticancer targets
Tolcher, A. W. (2002) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(02)00046-1 · Cited by 17
Hotte, S. J., Oza, A. M., Le, L., Maclean, M., Iacobucci, A. S., Corey, A. E., Fox, N., & Hirte, H. W. (2004) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(04)80216-7 · Cited by 2
Cited by
Apoptosis in cancer: from pathogenesis to treatment
Wong, R. S. (2011) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-30-87 · Cited by 2,836
Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis
Ouyang, L., Shi, Z., Zhao, S., Wang, F. ‐., Zhou, T. ‐., Liu, B., & Bao, J. ‐. (2012) · Cell Proliferation · doi:10.1111/j.1365-2184.2012.00845.x · Cited by 1,452
Understanding Apoptosis and Apoptotic Pathways Targeted Cancer Therapeutics
Jan, R., & Chaudhry, G.-E.-S. (2019) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2019.024 · Cited by 899
VDAC, a multi-functional mitochondrial protein regulating cell life and death
Shoshan-Barmatz, V., De Pinto, V., Zweckstetter, M., Raviv, Z., Keinan, N., & Arbel, N. (2010) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2010.03.002 · Cited by 782
Apoptosis and cancer: mutations within caspase genes
Ghavami, S., Hashemi, M., Ande, S. R., Yeganeh, B., Xiao, W., Eshraghi, M., Bus, C. J., Kadkhoda, K., Wiechec, E., Halayko, A. J., et al. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2009.066944 · Cited by 713
Metadata
- Authors
- Ghobrial, I. M., Witzig, T. E., & Adjei, A. A.
- Venue
- CA: A Cancer Journal for Clinicians
- Publisher
- Wiley
- Published
- 2005-05-01
- Volume
- 55
- Issue
- 3
- Pages
- 178-194
- ISSN
- 0007-9235 (ISSN-L)
- OpenAlex
- W2097786201
- Cited by
- 1,330
- References
- 92
- FWCI
- 16.13
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.